Therapeutic Advances in Hematology

Scope & Guideline

Empowering hematology professionals with cutting-edge findings.

Introduction

Delve into the academic richness of Therapeutic Advances in Hematology with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN2040-6207
PublisherSAGE PUBLICATIONS LTD
Support Open AccessYes
CountryUnited States
TypeJournal
Convergefrom 2010 to 2016, from 2018 to 2024
AbbreviationTHER ADV HEMATOL / Ther. Adv. Hematol.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND

Aims and Scopes

Therapeutic Advances in Hematology focuses on advancing the understanding and treatment of hematological disorders through innovative research and clinical studies. The journal emphasizes multidisciplinary approaches and encourages contributions that enhance patient care and treatment outcomes.
  1. Hematological Malignancies:
    Research on various hematological malignancies, including acute myeloid leukemia (AML), multiple myeloma, and lymphomas, focusing on novel therapeutic strategies and clinical outcomes.
  2. Transfusion Medicine and Hemostasis:
    Exploration of topics related to transfusion practices, management of bleeding disorders, and advancements in therapies for hemophilia and thrombocytopenia.
  3. Stem Cell Transplantation and Gene Therapy:
    Studies addressing the role of hematopoietic stem cell transplantation (HSCT), including conditioning regimens, donor selection, and the integration of gene therapy in treating hematological diseases.
  4. Patient-Reported Outcomes and Quality of Life:
    Research that evaluates the impact of hematological diseases and their treatments on patients' quality of life, incorporating patient-reported outcomes to inform treatment decisions.
  5. Innovative Treatment Modalities:
    Investigation into new treatment modalities such as CAR-T therapy, bispecific antibodies, and targeted therapies, with a focus on their efficacy and safety in various hematological conditions.
The journal has demonstrated a dynamic evolution in its research themes, with several emerging topics reflecting the latest advancements and priorities in hematology.
  1. Targeted and Personalized Therapies:
    A growing emphasis on targeted therapies, such as B-cell maturation antigen (BCMA) targeting in multiple myeloma, reflects the shift towards personalized medicine tailored to individual genetic profiles.
  2. Immunotherapy Advances:
    The rise of immunotherapeutic strategies, including CAR-T cell therapy and bispecific antibodies, indicates a significant trend towards harnessing the immune system to combat hematological malignancies.
  3. Real-World Evidence and Patient Experience:
    Increased attention to real-world evidence and patient-reported outcomes highlights the importance of understanding treatment impacts from the patient's perspective, influencing clinical practice.
  4. Innovations in Hematopoietic Stem Cell Transplantation:
    Research focusing on advancements in HSCT techniques, including the use of haploidentical donors and novel conditioning regimens, is becoming more prominent as these methods improve patient outcomes.
  5. Management of Rare Hematological Disorders:
    There is an emerging focus on the management and treatment of rare hematological conditions, such as aplastic anemia and paroxysmal nocturnal hemoglobinuria, addressing unmet medical needs.

Declining or Waning

While Therapeutic Advances in Hematology continues to publish impactful research, certain themes appear to be declining in prominence over recent years, potentially reflecting shifts in research focus or advancements in treatment options.
  1. Traditional Chemotherapy Approaches:
    The focus on traditional chemotherapy regimens appears to be waning, as newer targeted therapies and immunotherapies gain prominence in treatment paradigms for hematological malignancies.
  2. Historical Case Reports:
    The journal has seen a decrease in the publication of historical or anecdotal case reports, as the emphasis shifts towards larger, evidence-based studies and clinical trials.
  3. Generalized Treatment Guidelines:
    There is less emphasis on broad treatment guidelines that do not consider individual patient characteristics, as precision medicine and personalized treatment strategies become more prevalent.
  4. Epidemiological Studies:
    Research focused solely on epidemiological data without direct clinical implications seems to be less prioritized, as the journal emphasizes studies that directly impact treatment outcomes and patient care.

Similar Journals

Blood Cancer Journal

Championing accessible research for global impact.
Publisher: SPRINGERNATUREISSN: 2044-5385Frequency: 1 issue/year

Blood Cancer Journal, published by SPRINGERNATURE, is a leading open-access journal that has been at the forefront of hematology and oncology research since its inception in 2011. With an impressive impact factor and a commitment to disseminating high-quality research, it holds a prestigious Q1 ranking in both hematology and oncology categories as of 2023. The journal is dedicated to publishing innovative studies, comprehensive reviews, and insightful commentaries that advance our understanding of blood cancers, making it an essential resource for researchers, healthcare professionals, and students in the field. Its open-access model ensures that groundbreaking research is accessible to a global audience, promoting collaborative efforts to enhance treatment methodologies and patient outcomes. With a strong reputation illustrated by its Scopus rankings—8th in hematology and 30th in oncology—Blood Cancer Journal exemplifies excellence and leadership in the ever-evolving landscape of cancer research.

Journal of Hematology & Oncology

Advancing the Frontiers of Hematology and Oncology
Publisher: BMCISSN: Frequency: 1 issue/year

Journal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.

Journal of Hematology

Bridging Knowledge Gaps in Hematology
Publisher: ELMER PRESS INCISSN: 1927-1212Frequency: 4 issues/year

The Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.

LEUKEMIA RESEARCH

Exploring breakthroughs in hematology and oncology.
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0145-2126Frequency: 12 issues/year

Leukemia Research is a prominent academic journal dedicated to advancing the field of hematology and oncology, focusing on the latest research developments related to leukemia and other hematological disorders. Founded in 1977 and published by Pergamon-Elsevier Science Ltd in the United Kingdom, this esteemed journal has established itself as a vital resource for researchers and clinicians alike. With an impressive impact factor and categorized in the top quartiles of Cancer Research and Hematology, it provides a platform for high-quality research articles, reviews, and clinical studies that contribute to a deeper understanding of leukemia's complexities. Although not an Open Access journal, Leukemia Research ensures widespread dissemination of knowledge crucial for developing innovative treatment strategies and improving patient outcomes. Researchers, professionals, and students in the fields of hematology and oncology will find this journal an invaluable asset in staying at the forefront of leukemia research, as it prepares to expand its impact through converged years of publication extending into 2024.

CURRENT OPINION IN HEMATOLOGY

Transforming contemporary issues into clinical solutions.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1065-6251Frequency: 6 issues/year

CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.

Lancet Haematology

Fostering excellence in hematological research and practice.
Publisher: ELSEVIER SCI LTDISSN: 2352-3026Frequency: 12 issues/year

Lancet Haematology, published by Elsevier Science Ltd in the United Kingdom, is a premier peer-reviewed journal dedicated to advancing the field of hematology. With an impressive impact factor and listed in the Q1 category in hematology for 2023, this journal ranks #4 out of 137 in the Scopus database, boasting a 97th percentile indicating its influential role in disseminating high-quality research. Since its establishment in 2014, Lancet Haematology has provided a vital platform for researchers and clinicians to share groundbreaking studies, innovative treatment approaches, and novel therapeutic discoveries relevant to various hematological disorders. The journal does not operate under an open access model, but it offers multiple access options to facilitate engagement with its content. By bridging clinical practice and cutting-edge research, Lancet Haematology aims to foster the advancement of knowledge and improve patient outcomes in hematology, making it an essential read for professionals, researchers, and students alike.

Indian Journal of Hematology and Blood Transfusion

Elevating Knowledge: Your Source for Hematology Excellence
Publisher: SPRINGER INDIAISSN: 0971-4502Frequency: 4 issues/year

Indian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.

BLOOD

Exploring the Depths of Blood Science.
Publisher: AMER SOC HEMATOLOGYISSN: 0006-4971Frequency: 52 issues/year

BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.

Transplantation and Cellular Therapy

Empowering Discoveries in Cell Biology and Molecular Medicine.
Publisher: ELSEVIER SCIENCE INCISSN: 2666-6375Frequency: 12 issues/year

Transplantation and Cellular Therapy is a leading journal published by Elsevier Science Inc, dedicated to advancing the fields of transplantation, immunology, cell biology, and molecular medicine. With its ISSN of 2666-6375 and E-ISSN 2666-6367, this journal serves as a vital resource for researchers, practitioners, and students aiming to stay at the forefront of innovative therapies and clinical practices in transplantation. As of 2023, it holds an impressive Q1 ranking in multiple categories, including Cell Biology, Hematology, Immunology and Allergy, Molecular Medicine, and Transplantation, reflecting its high impact and relevance in the scientific community. The journal, operating from its base in the Netherlands, supports Open Access publishing to enhance the dissemination and accessibility of groundbreaking research. Acknowledging the significance of transplantation and cellular therapies in modern medicine, Transplantation and Cellular Therapy is poised to propel future discoveries and developments in these critical domains.

BLOOD REVIEWS

Advancing the frontiers of Hematology and Oncology.
Publisher: CHURCHILL LIVINGSTONEISSN: 0268-960XFrequency: 6 issues/year

BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.